Early life seizures and epileptic spasms inSTXBP1-related disorders

Abstract

ABSTRACTBackground and ObjectivesIndividuals with disease-causing variants inSTXBP1frequently have epilepsy onset in the first year of life with a variety of seizure types, including epileptic spasms. However, the impact of early-onset seizures and anti-seizure medication (ASM) on the risk of developing epileptic spasms and impact on their trajectory is poorly understood, limiting informed and anticipatory treatment, as well as trial design.MethodsWe retrospectively reconstructed seizure and medication histories in weekly intervals for individuals withSTXBP1-related disorders with epilepsy onset in the first year of life and quantitatively analyzed longitudinal seizure histories and medication response.ResultsWe included 61 individuals with early onset seizures, 29 of whom had epileptic spasms. Individuals with neonatal seizures were likely to have continued seizures after the neonatal period (25/26). The risk of developing epileptic spasms was not increased in individuals with neonatal seizures or early infantile seizures (21/41 vs. 8/16; OR 1, 95% CI 0.3-3.9,p= 1). We did not find any ASM associated with the development of epileptic spasms following prior seizures. Individuals with prior seizures (n = 16/21, 76%) had a higher risk to develop refractory epileptic spasms (n = 5/8, 63%, OR =1.9, 95% CI 0.2-14.6,p= 0.6). Individuals with refractory epileptic spasms had a later onset of epileptic spasms (n = 20, median 20 weeks) compared to individuals with non-refractory epileptic spasms (n = 8, median 13 weeks;p= 0.08). When assessing treatment response, we found that clonazepam (n = 3, OR 12.6, 95% CI 2.2-509.4;p< 0.01), clobazam (n=7, OR 3, 95% CI 1.6-6.2;p< 0.01), topiramate (n=9, OR 2.3, 95% CI 1.4-3.9;p< 0.01), and levetiracetam (n=16, OR 1.7, 95% CI 1.2-2.4;p< 0.01) were more likely to reduce seizure frequency and/or to maintain seizure freedom with regards to epileptic spasms than other medications.DiscussionWe provide a comprehensive assessment of early-onset seizures inSTXBP1-related disorders and show that the risk of epileptic spasms is not increased following a prior history of early-life seizures, nor by certain ASM. Our study provides baseline information for targeted treatment and prognostication in early-life seizures inSTXBP1-related disorders.